Wegovy Pill Surge Positions Novo Nordisk to Reclaim Ground in GLP-1 Race
Novo Nordisk’s newly introduced oral version of Wegovy is registering prescription volumes well above internal projections, reshaping the competitive dynamic in the fast-growing market for GLP-1 weight-management therapies. The Danish drugmaker reported 1.3 million prescriptions for the pill during the first quarter of 2026 and disclosed that the total had climbed to 2 million by […]